Please assess the completion status of the following clinical trial:

Trial Title: PXVX0200 (CVD103-HgR) vs Shanchol in Mali

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Able to understand the study and give consent (either written or through a process that involves audio tapes explaining all aspects of the study and the consent form in local languages \[Bambara and French\] followed by making a mark and signature by a literate witness)~* Healthy men or women, age 18 to 45 years (inclusive) without significant medical history~* Women of child-bearing potential must have negative urine pregnancy test at baseline, prior to vaccination. They must also be willing to use adequate birth control for the duration of the 28-day study and have additional pregnancy tests if indicated. Effective methods of birth control for this study include abstinence, intrauterine device (IUD), oral or depot contraceptive, or barrier plus spermicide~* Willingness to remain in the study area until at least 42 days after receipt of the first vaccine dose~Exclusion Criteria:~* Health care workers who have direct contact with patients who are immune deficient, HIV-positive, or have an unstable medical condition~* Clinically significant history of immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse~* History of an abnormal stool pattern or regular use of laxatives~* Previously received a licensed or investigational cholera vaccine~* History of cholera illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- PXVX0200 10E8 then placebo (Type: EXPERIMENTAL): PXVX0200 10E8 on day 0; Placebo on day 14
- Placebo, then PXVX0200 10E8 (Type: EXPERIMENTAL): Placebo on day 0; PXVX0200 10E8 on day 14
- PXVX0200 10E9 then Placebo (Type: EXPERIMENTAL): PXVX0200 10E9 on day 0; Placebo on day 14
- Placebo then PXVX0200 10E9 (Type: EXPERIMENTAL): Placebo on day 0; PXVX0200 10E9 on day 14
- Shanchol (Type: ACTIVE_COMPARATOR): Two doses of Shanchol, on day 0 and day 14

Based on this trial design, predict the completion outcome and termination type (if applicable).